17,261 trials
Postoperative Pain
Primary: Pain Intensity (PI) — 5.16; 6.43; 5.16 score on a scale (time-normalized AUC) — p=0.012
ST-segment Elevation Myocardial Infarction
Primary: Number of Participants With Spontaneous Reperfusion — 2 participants
Glaucoma · Open Angle or Ocular Hypertension
Primary: Intraocular Pressure (IOP) — 20.07; 19.89 mmHg
Crohn's Disease · Inflammatory Bowel Disease
Primary: Number of Participants With Flare Up of Crohn's Disease Through Month 12 — 6; 4; 0 participants
Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Maximum Tolerated Dose of Brentuximab Vedotin That Can be Combined With Ifosfamide, Carboplatin, and Etoposide Chemotherapy — 1.5 mg/kg
Gouty Arthritis
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 31; 52; 9; 15 Participants
HIV Infections
Primary: Change From Baseline in Log10 Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) at Week 48 of the Double-blind Period — 4.52; 4.50; 4.62; -1.78 Log10 copies/mL…
Pancreatic Mucinous-Cystic Neoplasm
Primary: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 3; 9 Participants
Infertility
Primary: Percentage of Oocyte Maturation — 49; 36; 76; 103 percentage of expected oocyte yield — p=<0.05
Chikungunya Virus Infection
Primary: Functional Anti-chikungunya Antibody Titers on Day 56 (28 Days Post Immunisation) Confirmed by Plaque Reduction Neutralization Test (PRNT50) — 50.2; 5.0; 12.9; 5.0 Titer…
Non-muscle Invasive Bladder Cancer (NMIBC)
Primary: Phase 1: Dose Limiting Toxicities (DLT) Following Intravesical Administration of ABI-009 — 0; 0; 0; 0 Participants
BRAF V600E Mutation
Primary: Number of Participants With Partial Response to Dabrafenib and Trametinib — 4 Participants
Diarrhea-predominant Irritable Bowel Syndrome
Primary: 24-hour Worst Abdominal Pain Scores (WAP) at Day 29 Compared to Baseline (Averaged Over the Week Prior to Each Respective Time Point) — -1.64; -2.30; -2.00; -1.69 Score…
Multiple Myeloma
Primary: Beta-adrenergically Mediated Gene Expression (Change From Baseline) — -0.407; 0.0099 Unitless — p=.017
Metastatic Colorectal Cancer
Primary: Rate of Patients Alive and Progression-free 6 Months After Inclusion. — 22 Nb of patients alive without progression